In vitro characterization of sarizotan metabolism: Hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome P450 inhibition

Drug Metabolism and Disposition

Volumn 38, Issue 6, 2010, Pages 905-916

  Gallemann, Dieter ^a   Wimmer, Elmar ^a   Höfer, Constance C ^b   Freisleben, Achim ^a   Fluck, Markus ^a   Ladstetter, Bernhard ^a   Dolgos, Hugues ^c  

^a MERCK KGAA   (Germany)

^b DMPKORE   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; SARIZOTAN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; ORGANIC CHEMICALS; OXIDOREDUCTASES, N-DEMETHYLATING; PRODRUGS;

EID: 77952309437     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029835     Document Type: Article

References (27)

1. Andersson T, Miners JO, Veronese ME, and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated both by S-mephenytoin hydroxylase and CYP3A4 isoforms. Br J Clin Pharmacol 38:131-137. (Pubitemid 24247754)
2. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503. (Pubitemid 35397059)
3. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
4. Bibbiani F, Costantini LC, Patel R, and Chase TN (2005) Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192:73-78. (Pubitemid 40208539)
5. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
7. Gertz M, Kilford PJ, Houston JB, and Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
8. Guillouzo A and Chesné C (1996) Xenobiotic metabolism in epithelial cell cultures, in Epithelial Cell Culture: A Practical Approach (Shaw JA ed) pp 67-85, IRL Press, Oxford.
9. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-727.
10. Houston JB and Galetin A (2003) Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab Rev 35:393-415.
11. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
12. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411. (Pubitemid 28477680)
13. Kilford PJ, Gertz M, Houston JB, and Galetin A (2008) Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 36:1194-1197. (Pubitemid 351929330)
14. Kovar A, Kroesser S, and Dolgos H (2006) The effect of erythromycin on the pharmacokinetics of sarizotan and its metabolites in healthy male volunteers (Abstract P01.100). Int J Neuropsychopharmacol 9 (Suppl 1):S127.
15. Kroesser S, Fluck M, Wolna P, and Kovar A (2006a) Investigation of the bioavailability of sarizotan and the pharmacokinetic effects of food (Abstract P01.099). Int J Neuropsychopharmacol 9 (Suppl 1):S127.099.
16. Krösser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, and Kovar A (2006b) Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 62:277-284.
17. Krösser S, Tillner J, Fluck M, Ungethüm W, Wolna P, and Kovar A (2007) Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects. Int J Clin Pharmacol Ther 45:271-280. (Pubitemid 46739097)
18. Masimirembwa CM, Bredberg U, and Andersson TB (2003) Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515-528. (Pubitemid 36801870)
19. Masimirembwa CM, Thompson R, and Andersson TB (2001) In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 4:245-263.
20. Ortiz de Montellano PR and Mathews JM (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne-protoporphyrin IX adduct. Biochem J 195:761-764.
21. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
22. Rowland M, Benet LZ, and Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
23. Thompson TN (2000) Early ADME in support of drug discovery: the role of metabolic stability studies. Curr Drug Metab 1:215-241.
24. Tillner J, Kroesser S, Fluck M, Ungethuem W, and Kovar A (2006) Sarizotan: a review of its clinical pharmacokinetics. Mov Disord 21:S124.
25. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297:326-337.
26. Wilkinson GR and Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
27. Williams JA, Hurst SI, Bauman J, Jones BC, Hyland R, Gibbs JP, Obach RS, and Ball SE (2003) Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 4:527-534.